Complexo Hospitalario Universitario de Lugo
Centro de atención
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milán, ItaliaPublicacións en colaboración con investigadores/as de Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (7)
2024
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study
The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383
2023
-
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry
International Journal of Antimicrobial Agents, Vol. 62, Núm. 4
-
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
Journal of hematology & oncology
2020
-
The first ever external quality assessment program on urinary sediment in a country of sub-saharan Africa based on new smartphone technologies
Clinical Laboratory, Vol. 66, Núm. 7, pp. 1277-1284
2017
-
A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis
American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74
2015
-
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility
American Journal of Human Genetics, Vol. 96, Núm. 4, pp. 565-580